Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
2.250
-0.320 (-12.45%)
At close: Nov 3, 2025, 4:00 PM EST
2.200
-0.050 (-2.22%)
Pre-market: Nov 4, 2025, 6:37 AM EST
Company Description
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules.
Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Protagenic Therapeutics, Inc.
| Country | United States |
| Founded | 1994 |
| IPO Date | Jan 5, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Barrett Evans |
Contact Details
Address: 701 Anacapa Street, Suite C Santa Barbara, California 93101 United States | |
| Phone | (805) 699-5596 |
| Website | phytanix.com |
Stock Details
| Ticker Symbol | PTIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N301 |
| ISIN Number | US74365N2027 |
| Employer ID | 06-1390025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Barrett Evans | President, Chief Executive Officer and Director |
| Dr. Garo H. Armen Ph.D. | Co-Founder and Executive Chairman of the Board |
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer and Secretary |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer |
| Dr. Andrew Slee Ph.D. | Chief Development Officer |
| Colin G. Stott B.Sc. | Chief Operating Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2025 | 8-K | Current Report |
| Oct 24, 2025 | 424B5 | Filing |
| Sep 17, 2025 | 8-K/A | [Amend] Current report |
| Sep 10, 2025 | 10-QT | Filing |
| Aug 28, 2025 | 8-K/A | [Amend] Current report |
| Aug 25, 2025 | SCHEDULE 13G/A | Filing |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 8-K | Current Report |